
Key Points
- 01Lilly agreed to acquire Calytrix Bio for up to $1.5 billion in cash
- 02Deal focuses on a preclinical antibody for essential thrombocythemia and myelofibrosis
- 03Acquisition is Lilly’s 15th company purchase in 2026, exceeding $30 billion spent
- 04Transaction broadens Lilly’s footprint in myeloproliferative neoplasms and hematology
Lilly signs $1.5 billion deal for Calytrix Bio
Eli Lilly and Company has entered a definitive agreement to acquire Calytrix Bio, a privately held biotechnology company developing therapies for myeloproliferative neoplasms. Under the terms agreed on November 16, 2026, Calytrix shareholders could receive up to $1.5 billion in cash. The consideration consists of an upfront payment plus additional payments tied to the achievement of specified clinical and regulatory milestones.
The acquisition target is headquartered in Wellesley, Massachusetts, and focuses on rare blood cancers, particularly essential thrombocythemia and myelofibrosis. The transaction continues a pattern of Lilly using acquisitions to expand its pipeline in specialized disease areas.
Focus on Calytrix’s lead antibody program
Calytrix’s lead asset is an investigational biparatopic antibody designed for mutant calreticulin–driven essential thrombocythemia and myelofibrosis. The program is preclinical and targets both Type 1 and Type 2 mutant calreticulin, with the goal of delivering pan-mutant activity. It is intended to offer disease-modifying potential along with a safety and convenience profile that supports early intervention and long-term treatment.
These two conditions are forms of myeloproliferative neoplasms in which the bone marrow produces excessive abnormal blood cells, leading to complications such as bone marrow scarring and blood clots. Existing therapies for these diseases, including blood transfusions and JAK inhibitor drugs, primarily manage symptoms and complications rather than directly modifying the underlying disease biology.
Strategic expansion in myeloproliferative neoplasms and hematology
The Calytrix transaction broadens Lilly’s presence in the myeloproliferative neoplasm field and strengthens its hematology business. Lilly already markets Jaypirca, a blood cancer medicine cleared by the U.S. Food and Drug Administration, and is adding Calytrix’s experimental antibody to this portfolio. The deal is also expected to support Lilly’s objective of expanding beyond its diabetes and weight-loss franchise, which remains its main growth engine.
In August, Lilly agreed to acquire Merida Biosciences for up to $2.875 billion, adding therapies that target disease-causing antibodies. Together with the Calytrix agreement, these transactions contribute to Lilly’s efforts to deepen its capabilities in immune and blood-related diseases through external innovation.
Lilly’s 2026 dealmaking streak and Calytrix’s backing
With the Calytrix Bio agreement, Lilly has now announced 15 company acquisitions in 2026, the highest total among large biopharmaceutical groups. These transactions represent more than $30 billion in disclosed spending, with most of the acquired firms being privately held startups. Other large pharmaceutical companies, including GSK, Gilead Sciences and Novartis, have each announced three drug-company acquisitions in 2026.
Calytrix was founded in 2025 by J.P. Morgan Life Sciences Private Capital. The company was launched with a Series A financing co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners, followed by a Series B round led by Avoro Ventures. Centerview Partners is serving as exclusive financial adviser to Calytrix, with Goodwin Procter as legal counsel, while Paul, Weiss, Rifkind, Wharton & Garrison is acting as legal counsel to Lilly.
Key Takeaways
- 01Lilly is committing up to $1.5 billion to secure a preclinical, mutation-targeted antibody platform for rare blood cancers.
- 02The Calytrix acquisition fits into a broader 2026 strategy in which Lilly has used 15 deals and more than $30 billion of capital to build its pipeline.
- 03By adding Calytrix’s program alongside Jaypirca and the planned Merida Biosciences acquisition, Lilly is consolidating a larger presence in hematology and myeloproliferative neoplasms.
References
- https://www.biopharmadive.com/news/lilly-calytrix-bio-acquire-deal-myelofibrosis-essential-thrombocythemiaenial-/874719/?.tsrc=rss
- https://www.investing.com/news/stock-market-news/lilly-to-buy-calytrix-bio-for-up-to-15-billion-5029412
- https://www.prnewswire.com/news-releases/calytrix-bio-enters-an-agreement-to-be-acquired-by-lilly-to-advance-outcomes-for-patients-living-with-essential-thrombocythemia-and-myelofibrosis-302940325.html
- https://qz.com/eli-lilly-calytrix-bio-acquisition-blood-cancer-111626